* Teva can sell generic version of Crohn's drug in 2012
* Other terms of settlement agreement not disclosed
* Entocort EC global sales about $100 million in 2009
* Astrazeneca shares flat
(Adds sales figure, shares)
LONDON, May 18 AstraZeneca (AZN.L) has settled a
U.S. patent dispute with Teva Pharmaceuticals (TEVA.TA) by
allowing Teva to sell a generic version of Astra's Entocort EC
drug for Crohn's disease from 2012.
Teva has received a licence to enter the U.S. market with
its generic version of the capsules, which contain the active
ingredient budesonide, on Feb. 15, 2012, subject to regulatory
approval, or earlier in certain circumstances.
Other terms of the settlement were not disclosed, but Astra
said on Tuesday Teva had conceded that patents protecting
Entocort EC were valid and enforceable.
The settlement is a small positive for Astra, although
Entocort EC is not a major seller with global sales last year of
around $100 million, equivalent to about 0.3 percent of the
AstraZeneca shares were flat, in line with an broadly
unchanged European healthcare sector .SXDP by 0800 GMT.
Merck (MRK.N), which has had a longstanding relationship
with Astra entitling it to a royalty on U.S. sales of certain
Astra drugs, has also entered into the settlement agreement.
(Reporting by Ben Hirschler; Editing by Erica Billingham and